24.06.2010 • NewsReliance Industriesportfolioshale

Reliance to Invest $1.36 Billion in U.S. Shale Gas Venture

Reliance Industries will invest $1.36 billion in shale assets of Pioneer Natural Resources, as the Indian energy major looks to build its presence in the U.S. shale gas sector. Under the agreement, Pioneer will sell a 45% stake in its Eagle Ford shale acreage in south Texas to Reliance for $1.15 billion, the U.S. firm said a statement.

Reliance has also entered into an agreement with Pioneers existing partner in the Eagle Ford Shale play for about $210 million. The deal is the second of its kind this year for Reliance, a petrochemicals-to-refining giant with a market value of $75 billion.

In April, Reliance agreed to pay $1.7 billion to Atlas Energy to form a joint venture and own a 40% stake in Atlas' Marcellus Shale operations in the eastern United States.

Companies from around the globe are increasingly investing in U.S. shale plays - underground rock formations that hold reserves of oil and natural gas. Shale gas accounts for between 15% and 20% of U.S. gas production but is expected to quadruple in coming years, touching off a scramble among producers large and small for access to resources.

(6/24/2010)

Company

Reliance Industries

9th Floor, Nariman Point
400 021 Mumbai
India

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.